

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

van Weeghel et al.

Serial No.: To be assigned

Filed: March 1, 2004

For: DETERMINATION AND
QUANTIFICATION OF RED BLOOD
CELL POPULATIONS IN SAMPLES

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 2183-6372US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EV326919638US

Date of Deposit with USPS: March 1, 2004

Person making Deposit: Christopher Houghton

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 or PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

U.S. Patent Documents

<u>U.S. Patent No.</u>	<u>Publication Date</u>	<u>Patentee</u>
US - 5,962,234	10-05-1999	Golbus

Foreign Patent Documents

<u>Document No.</u>	<u>Publication Date</u>	<u>Patentee</u>
EP 0 971 233 A1	01-12-2000	Immunotech S.A.
WO 03/021275 A1	03-13-2003	IQ Corporation B.V.

Other Documents

PCT International Search Report, PCT/NL02/00579, dated November 7, 2002.

PCT International Preliminary Examination Report, PCT/NL02/00579, dated July 16, 2003, 3 pages.

DAVIS, et al., Detection of fetal red cells in fetomaternal hemorrhage using a fetal hemoglobin monoclonal antibody by flow cytometry, Immunohematology, August 1998, pp. 749-56, Vol. 38.

BRADY et al., Expression of the human carbonic anhydrase I gene is activated late in fetal erythroid development and regulated by stage-specific trans-acting factors, British Journal of Haematology, 1990, pp. 135-42, Vol. 76.

Attorney Docket No.: 2183-6372US

This Information Disclosure Statement is filed within three (3) months of the filing date of the above-identified application, and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee pursuant to 37 C.F.R. § 1.17(p) is required.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Allen C. Turner", with a stylized flourish at the end.

Allen C. Turner

Registration No. 33,041

Attorney for Applicant(s)

TRASKBRITT, P.C.

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: February 26, 2004

ACT/bv

Enclosures: Form PTO-1449 or PTO/SB/08

Cited Documents

Document in ProLaw

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	To be assigned
Filing Date	February 27, 2004
First Named Inventor	Van Weeghel et al.
Group Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	2183-6372US

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(use as many sheets as necessary)*

Sheet 2 of 2

Complete if Known

Application Number	To be assigned
Filing Date	February 27, 2004
First Named Inventor	van Weeghel et al.
Group Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	2183-63721JS

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PCT International Search Report, PCT/NL02/00579, dated November 7, 2002.	
		PCT International Preliminary Examination Report, PCT/NL02/00579, dated July 16, 2003, 3 pages.	
		DAVIS, et al., Detection of fetal red cells in fetomaternal hemorrhage using a fetal hemoglobin monoclonal antibody by flow cytometry, Immunohematology, August 1998, pp. 749-56, Vol. 38.	
		BRADY et al., Expression of the human carbonic anhydrase I gene is activated late in fetal erythroid development and regulated by stage-specific trans-acting factors, British Journal of Haematology, 1990, pp. 135-42, Vol. 76.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.